Browse the evidence

Semaglutide has been approved by the FDA for the treatment of obesity or overweight.

Healthcare providers can prescribe semaglutide for weight management in eligible patients.

Mean 12-month weight loss was -2.4 kg.

Practitioners can expect an average weight loss of about 2.4 kg in similar interventions.

At 42 months, participants regained weight but did not exceed baseline, with a mean change of -0.5 kg.

Long-term maintenance strategies can help prevent exceeding initial weight after loss.

People with fourth and fifth quintiles of total energy intake are likely to have lower risks of all-cause and expanded cardiovascular disease (CVD) mortality.

Increasing total energy intake within certain limits may be beneficial for longevity in type 2 diabetes patients.

People with fifth quintiles of total energy intake are likely to have decreased non-expanded CVD mortality.

Higher total energy intake may reduce the risk of non-expanded CVD mortality in type 2 diabetes patients.

Fat intake was associated with all-cause, expanded and non-expanded CVD mortality among males with T2DM.

Monitoring fat intake may be important for reducing mortality risk in male patients with type 2 diabetes.

Excess weight and elevated Body Mass Index are associated with lower adherence to the Mediterranean diet.

Addressing weight issues may improve adherence to the Mediterranean diet.

After educational intervention, adherence to the Mediterranean diet increased from a score of 6.22 to 6.84.

Educational programs can effectively enhance adherence to the Mediterranean diet.

Four positive signals were found at the system organ classes level for tirzepatide.

Monitoring for specific adverse events is crucial for patients on tirzepatide.

Two patients achieved significant weight loss of 16% and 12.6% in under 9 months using semaglutide.

Clinicians can expect significant weight loss outcomes in similar patients using semaglutide.

There was a significant reduction in systolic blood pressure, mean pressure, and aortic systolic pressure in both groups.

Implementing home-based exercise programs can effectively lower blood pressure in individuals with metabolic syndrome.

Pulse wave velocity, aortic pulse pressure, and aortic diastolic pressure showed significant reductions only in Group 2.

Adding IT support to exercise programs may enhance vascular health outcomes.

DTC fitness genetic tests promise insights about nutrition, healthy aging, weight loss, and athletic aptitude.

Consumers should critically evaluate the claims made by DTC fitness genetic tests.

Most ultraprocessed foods overlap with foods high in saturated fat, added sugars, and sodium.

Practitioners should consider the nutritional content of UPFs when advising clients.

52.4% of powerlifters reported stretching, with 84.4% performing static stretches and 90.4% performing dynamic stretches.

Coaches and athletes should be aware that a significant portion of powerlifters engage in stretching, particularly static and dynamic forms.

77.8% of powerlifters performed stretching before resistance training.

It is common practice among powerlifters to incorporate stretching before their training sessions.

66.9% of powerlifters programmed stretching themselves.

Powerlifters often take initiative in planning their own stretching routines, which may influence their training outcomes.

The obesity epidemic is associated with increased risk of cardiovascular disease, type 2 diabetes, many forms of cancer, gallbladder disease, and osteoarthritis.

Healthcare providers should consider these risks when addressing obesity in patients.

Tirzepatide was recently approved by the FDA for the management of type 2 diabetes.

Tirzepatide can be utilized in clinical settings for managing type 2 diabetes, with potential implications for weight loss.

Metabolic and bariatric surgery is independently associated with a lower risk of incident cancer than nonsurgical obesity care.

Practitioners should consider metabolic and bariatric surgery as a viable option for reducing cancer risk in obese patients.

Among patients with monthly counseling or more, the 10-year cumulative incidence of death and cardiovascular events was 33.0% compared with 38.1% for less than monthly counseling.

Practitioners should consider increasing the frequency of lifestyle counseling for diabetic patients to improve long-term outcomes.

Higher frequency of lifestyle counseling was associated with lower incidence of death and cardiovascular events.

Increasing lifestyle counseling frequency may lead to better health outcomes for diabetic patients.

No significant differences in adverse events were observed between semaglutide and comparator groups.

This suggests that semaglutide is as safe as other treatments in terms of adverse events.

Fifty-six studies reported statistically significant findings in outcome measures.

Interventions can lead to measurable improvements in health outcomes.